Liaoning Chengda Biotechnology (688739.SH) reported a net profit of 334 million yuan in 2024, a year-on-year decrease of 28.4%.

Liaoning Chengda Biotechnology (688739.SH) released its 2024 annual performance report. The company's total operating revenue for 2024 was 1.676 billion RMB, a decrease of 4.22% year-on-year. The net profit attributable to the owners of the parent company was 334 million RMB, a decrease of 28.40% year-on-year. The net profit attributable to the owners of the parent company, excluding non-recurring gains and losses, was 315 million RMB, a decrease of 23.75% year-on-year. The basic earnings per share were 0.81 RMB. During the reporting period, the company's operating profit and total profit decreased significantly year-on-year, mainly due to: 1. A slight decrease in operating income; 2. Continued increase in research and development expenses; 3. Decline in the valuation of certain investments by the company.